Role of retinol-binding protein 4 in the pathogenesis of Type 2 diabetes

References

• Lazar M. The humoral side of insulin resistance. Nat. Med.12(1), 43–44 (2006).
   PubMedGoogle Scholar
• Hotamisligil GS, Shargill NS, Spiegleman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science259(5091), 87–91 (1993).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature372(6505), 425–432 (1994).
   PubMed Web of Science ®Google Scholar
• Ogawa Y, Masuzaki H, Hosoda K et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes48(9), 1822–1829 (1999).
   PubMed Web of Science ®Google Scholar
• Minokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature415(6869), 339–343 (2002).
   PubMed Web of Science ®Google Scholar
• Aizawa-Abe M, Ogawa Y, Matsuzaki H et al. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest.105(9), 1243–1252 (2000).
   PubMed Web of Science ®Google Scholar
• Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem.270(45), 26746–26749 (1995).
   PubMed Web of Science ®Google Scholar
• Hu E, Liang P, Spiegelman BM. Adipo Q is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem.271(18), 10697–10703 (1996).
   PubMed Web of Science ®Google Scholar
• Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. (Tokyo)120, 803–812 (1996).
   PubMed Web of Science ®Google Scholar
• Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun.221(2), 286–289 (1996).
   PubMed Web of Science ®Google Scholar
• Matsuda M, Shimomura I, Sata M et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo–vascular axis. J. Biol. Chem.277(40), 37487–37491 (2002).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein, adiponectin. Circulation100(25), 2473–2476 (1999).
   PubMed Web of Science ®Google Scholar
• Ouchi N, Kihara S, Arita T et al. Adipocyte-derived plasma protein adiponectin, suppressed lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation103(8), 1057–1063 (2001).
   PubMed Web of Science ®Google Scholar
• Holcomb IN, Kobakoff RC, Chan B et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J.19(15), 4046–4055 (2000).
   PubMed Web of Science ®Google Scholar
• Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature409(6818), 307–312 (2001).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ. The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene305(1), 27–34 (2003).
   PubMed Web of Science ®Google Scholar
• Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat. Med.2(7), 800–803 (1996).
   PubMed Web of Science ®Google Scholar
• Hamsten A, deFaire U, Walldius G et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet2(8549), 3–9 (1987).
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Habener JF. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance using hybridization in situ. Endocrinology121(5), 1616–1626 (1987).
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J. Clin. Endocrinol. Metab.82(12), 4196–4200 (1997).
   PubMed Web of Science ®Google Scholar
• Gerhardt CC, Romerol A, Cancell R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adiopcytes. Mol. Cell. Endocrinol.175(1–2), 81–92 (2001).
   PubMed Web of Science ®Google Scholar
• Gu L, Okada Y, Clinton SK et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell.2(2), 275–281 (1998).
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest.112(12), 1785–1788 (2003).
   PubMed Web of Science ®Google Scholar
• Kamei N, Tobe K, Suzuki R et al. Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem.281(36), 26602–26614 (2006).
   PubMed Web of Science ®Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science307(5708), 426–30 (2005). This paper was retracted in Science318(5850), 565 (2007).
   PubMed Web of Science ®Google Scholar
• Yang RZ, Lee MJ, Hu H et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab.290(16), E1253–E1261 (2006).
   PubMed Web of Science ®Google Scholar
• Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and Type 2 diabetes. Nature436(7049), 356–362 (2005).
   PubMed Web of Science ®Google Scholar
• Kono T, Robinson FW, Blevins TL, Ezaki O. Evidence that translocation of the glucose transport activity is the major mechanism of insulin action on glucose transport cells. J. Biol. Chem.257(18), 10942–10947 (1982).
   PubMedGoogle Scholar
• Shepherd PR, Kahn BB. Glucose transporters and insulin action. N. Engl. J. Med.341(4), 248–257 (1999).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Jacot E, Jeguier E, Maeder E, Wahren J, Felber JP. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes30(12), 1000–1007 (1981).
   PubMed Web of Science ®Google Scholar
• Abel ED, Peroni O, Kim JK et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature409(6821), 729–733 (2001).
   PubMed Web of Science ®Google Scholar
• Tsutsumi C, Okuno M, Tannous L et al. Retinoids and retinoid-binding protein expression in rat adipocytes. J. Biol. Chem.267(3), 1805–1810 (1992).
   PubMed Web of Science ®Google Scholar
• Quadro L, Blaner WS, Salchow DJ et al. Impaired retinal function and vitamin A availability in mice lacking retinol binding protein. EMBO J.18(17), 4633–4644 (1999).
   PubMed Web of Science ®Google Scholar
• Graham TE, Yang Q, Bluher M et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med.354(24), 2552–2563 (2006).
   PubMed Web of Science ®Google Scholar
• Takashima N, Tomoike H, Iwai N. (Letter to the editor). N. Engl. J. Med.355(13), 1392 (2006).
   PubMedGoogle Scholar
• Erikstrup C, Mortensen O, Pedersen BK. (Letter to the editor). N. Engl. J. Med.355(13), 1393–1394 (2006).
   PubMed Web of Science ®Google Scholar
• Janke J, Engeli S, Boschmann M et al. Retinol-binding protein 4 in human obesity. Diabetes55(10), 2805–2810 (2006).
   PubMed Web of Science ®Google Scholar
• Kloting N, Graham TE, Berndt J et al. Serum retiniol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab.6(1), 79–87 (2007)
   PubMed Web of Science ®Google Scholar
• Cho YM, Youn BS, Lee H et al. Plasma retinol-binding protein protein-4 concentrations are elevated in numan subjects with impaired glucose tolerance and Type 2 diabetes. Diabetes Care29(11), 2457–2461 (2006).
   PubMed Web of Science ®Google Scholar
• Lee DC, Lee JW, Im JA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism56(3), 327–331 (2007).
   PubMed Web of Science ®Google Scholar
• Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: Association with subclinical inflammation. J. Clin. Endocrinol. Metab.92(5), 1971–1974 (2007).
   PubMed Web of Science ®Google Scholar
• Jia W, Wu H, Bao Y et al. Association of serum retinol binding protein 4 and visceral adiposity in Chinese subjects with and without Type 2 diabetes. J. Clin. Endocrinol. Metab.92(8), 3224–3229 (2007).
   PubMed Web of Science ®Google Scholar
• Qi Q, Yu Z, Ye X et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J. Clin. Endocrinol. Metab.92(12), 4827–4834 (2007).
   PubMed Web of Science ®Google Scholar
• Gavi S, Stuart LM, Kelly P et al. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type diabetes. J. Clin. Endocrinol. Metab.92(5), 1886–1890 (2007).
   PubMed Web of Science ®Google Scholar
• Stefan N, Hennige AM, Staiger H et al. High circulating retinol binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocelluar fat in humans. Diabetes Care30(5), 1173–1178 (2007).
   PubMed Web of Science ®Google Scholar
• Vitkova M, Klimcakova E, Kovacikova M et al. Plasma levels and adipose tissue messenger ribonucleic acid expression of retinol-binding protein 4 are reduced during calorie restriction in obese subjects but are not related ro diet-induced changes in insulin sensitivity. J. Clin. Endocrinol. Metab.92(6), 2330–2335 (2007).
   PubMedGoogle Scholar
• Yao-Borengasser A, Varma V, Bodles AM et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J. Clin. Endocrinol. Metab.92(7), 2590–2597 (2007).
   PubMed Web of Science ®Google Scholar
• Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. Circulating retinol binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care30(7), 1802–1806 (2007).
   PubMed Web of Science ®Google Scholar
• Graham TE, Wason CJ, Bluher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia50(4), 814–823 (2007).
   PubMed Web of Science ®Google Scholar
• Von Eynatten M, Lepper PM, Liu D et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with Type 2 diabetes or coronary artery disease. Diabetologia50(9), 1930–1937 (2007).
   PubMed Web of Science ®Google Scholar
• Munkhtulga L, Nakayama K, Utsumi N et al. Identified of a regulatory SNP in the retinol binding protein 4 gene associated with Type 2 diabetes in Mongolia. Hum. Genet.120(6), 879–888 (2007).
   PubMedGoogle Scholar
• Craig RL, Chu WS, Elbein SC. Retinol binding protein 4 as a candidate gene for Type 2 diabetes and prediabetic intermediate traits. Mol. Gen. Metab.90(3), 338–344 (2007).
   PubMedGoogle Scholar
• Kovacs P, Geyer M, Berndt J et al. Effects of genetic variation in the human retinol binding protein-4 gene (RBP4) on insulin resistance and fat depot specific mRNA expression. Diabetes56(12), 3095–4100 (2007).
   PubMed Web of Science ®Google Scholar
• Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr. Rev.28(5), 463–491 (2007).
   PubMed Web of Science ®Google Scholar
• Mothe I, Van Obberghen E. Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, and 731, modulates insulin action. J. Biol. Chem.271(19), 11222–11227 (1996).
   PubMed Web of Science ®Google Scholar
• Laurent S, Lacolley P, Brunel P, Laloux B, Pannier B, Safer M. Flow-dependent vasodilation of brachial artery in essential hypertension. Am. J. Physiol.258(4 Pt 2), H1004–H1011 (1990).
   PubMedGoogle Scholar
• Correti MC, Anderson TJ, Benjamin EJ et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery. A report of the international brachial artery reactivity task force. J. Am. Coll. Cardiol.39(2), 257–265 (2002).
   PubMedGoogle Scholar
• Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of Type 2 diabetes patients. J. Clin. Endocrinol. Metab.92(7), 2712–2719 (2007).
   PubMed Web of Science ®Google Scholar
• Matarese V, Lodish HF. Specific uptake of retinol binding protein by variant F9 cell lines. J. Biol. Chem.268(25), 18859–18865 (1993).
   PubMedGoogle Scholar
• Christensen E, Moskaug JO, Vorum H et al. Evidence for an essential role of megalin in transepithelial transport of retinol. J. Am. Soc. Nephrol.10(4), 685–695 (1999).
   PubMed Web of Science ®Google Scholar
• Rodondi N, Darioli R, Ramelet AA et al. High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis-retinoic acid therapy for acne: a pharmacogenetic study. Ann. Intern. Med.136(8), 582–589 (2002).
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Xu HE, Lambert MH, Wilson TM. Peroxisome proliferator-activated receptor: from genes to physiology. Recent Prog. Horm. Res.56, 239–263 (2001).
   PubMedGoogle Scholar
• Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog. Nucleic Acid Res. Mol. Biol.63, 139–188 (1999).
   PubMedGoogle Scholar
• Duester G, Mic FA, Molotkov A. Cytosolic retinoid dehydrogenases govern ubiquitous metabolism of retinol to retinaldehyde followed by tissue-specific metabolism to retinoic acid. Chem. Biol. Interact.143–144, 201–210 (2003).
   Google Scholar
• Ziouzenkova O, Orasanu G, Sharlach M et al. Retinaldehyde repress adipogenesis and diet-induced obesity. Nat. Med.13(6), 695–702 (2007).
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med.340(12), 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Kang ES, Kim HJ, Ahn CW et al. Relationship of serum high sensitivity C reactive protein to metabolic syndrome and microvascular complications in Type 2 diabetes. Diabetes Res. Clin. Pract.69(2), 151–159 (2005).
   PubMedGoogle Scholar
• Baeten JM, Richardson BA, Bankson DD et al. Use of serum retino-binding protein for prediction of vitamin A deficiency: effects of HIV-1 infection, protein malnutrition, and the acute phase response. Am. J. Clin. Nutr.79(2), 218–225 (2004).
   PubMed Web of Science ®Google Scholar
• Berendji-Grun D, Kolb-Bachofen V, Kroncke KD. Nitric oxide inhibits endothelial IL-1[β]-induced ICAM-1 gene expression at the transcriptional level deceasing Sp-1 and AP-1 activity. Mol. Med.7(11), 748–754 (2001).
   PubMedGoogle Scholar
• Haider DG, Schindler K, Mittermayer F et al. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clin. Pharmacol. Ther.81(4), 580–585 (2007).
   PubMedGoogle Scholar
• Dandona P, Ghanim H, Mohanty P, Sia LC, Viswanathan P. Retinol binding protein-4 between lean, obese and Type 2 diabetic subjects: lack of the effect of caloric restriction and rosiglitazone. Diabetes56(Suppl. 1), A469 (2007).
   Google Scholar
• Sasaki R, Nishimura H, Hoshino H et al. Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice. Biochem. Pharmacol.74(11), 1619–1627 (2007).
   PubMed Web of Science ®Google Scholar
• Haider D, Schindler K, Prager G et al. Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J. Clin. Endocrinol. Metab.92(3), 1168–1171 (2007).
   PubMed Web of Science ®Google Scholar
• Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism36(1), 54–59 (1987).
   PubMed Web of Science ®Google Scholar
• Shibasaki M, Takahashi K, Itou T et al. Alterations of insulin sensitivity by the impanation of 3T3-L1 cells in nude mice. A role for TNF-α? Diabetologia45(4), 518–526 (2002).
   PubMedGoogle Scholar
• Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes37(12), 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• Cabre A, Lazaro I, Girono J et al. Retinol-binding protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in Type 2 diabetes. J. Intern. Med.262(4), 496–503 (2007).
   PubMedGoogle Scholar
• Raila J, Henze A, Spranger J, Mohlig M, Pfeiffer AFH, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in Type 2 diabetic patients. Kidney Int.72(4), 505–511 (2007).
   PubMed Web of Science ®Google Scholar
• Seo JA, Kim NH, Park SY et al. Serum retinol-binding protein 4 levels are elevated in non-alcholic fatty liver desease. Clin. Endocrinol. (Oxf.). (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Wu H, Jia W, Bao Y et al. Serum retinol binding protein 4 and nonalcoholic fatty liver desease in patients with Type 2 diabetes mellitus. Diabetes Res. Clin. Pract.79(2), 185–190 (2008).
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcholic fatty liver disease. J. Clin. Endocrinol. Metab.91(12), 4752–4761 (2006).
   Google Scholar